Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.67 +1.20%

+$0.15 today

Market cap
$336.08M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.18M

Average 0.09M

Returns on capital

Lyell Immunopharma, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-110.6%

avg -49.3%

ROIC

-68.0%

avg -38.1%

ROA

-80.7%

avg -38.5%

Analysis

ROIC is currently the strongest return metric at -68.0% versus its period average of -38.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Lynn Seely

Principal Executive Officer, President, CEO & DirectorUSD 1.13M6763.35K0.27%

Stephen J. Hill

Chief Operating OfficerUSD 830.56K5516.73K0.07%

Gary Lee

Chief Scientific OfficerUSD 786.81K49——

Richard D. Klausner

Founder & Executive ChairmanUSD 85K74——

Crystal L. Mackall

Founder & Scientific Advisor—65——

Ann Tomlin

Chief Human Resources Officer————

Smital Shah

Principal Financial Officer, CFO & Chief Business Officer—500<0.01%

Mark A. Meltz

General Counsel & Corporate Secretary—5250.00K0.21%

Nellie Dillery

Director of Accounting————

Stanley R. Riddell

Founder & Scientific Advisor————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 10, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

4

$75.00M

Sells

29

$612,747.03

Net Transaction Value

+$74.39M

Net buying

Most Active

Lee Gary K.

6 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 10, 26

Lee Gary K.

Direct

Sell$2.1K
Nov 10, 26

Hill Stephen J.

Direct

Sell$1.4K
Nov 10, 26

Seely Lynn

Direct

Sell$8.7K
Nov 10, 26

Bulis Veronica Sanchez

Direct

Sell$6.6K
Nov 4, 26

ARCH Venture Partners IX, LLC

Indirect

Buy$25M
Nov 4, 26

ARCH Venture Fund XIII, L.P.

Indirect

Buy$25M
Oct 12, 26

Aguirre Jarrad Mattieu

Direct

Sell$3.6K
Sep 10, 26

Shook David

Direct

Sell$6.4K
Aug 21, 26

Seely Lynn

Direct

Sell$149K
Aug 21, 26

Hill Stephen J.

Direct

Sell$15.4K

1–10 of 33

Summary

Insiders reported 4 buys worth $75.00M and 29 sells worth $612,747.03 over the last 12 months. That adds up to net buying of $74.39M. Lee Gary K. was the most active insider with 6 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-92.5%
+511.4% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at -92.5% over three years. Forward estimates point to Revenue at +511.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Lyell Immunopharma, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about LYEL's management, answered from reported figures.

Who manages LYEL?

Lyell Immunopharma, Inc. (LYEL) lists 10 active executives. The top listed executive is Crystal L. Mackall, Founder & Scientific Advisor.

Are LYEL insiders buying or selling?

Recent insider activity shows net buying of $102.84M.